By Adriano Marchese

 

Novavax Inc. said Wednesday that Canada's health regulator has approved its Covid-19 vaccine in adolescents aged 12 through 17.

The vaccine developer said that Health Canada approved its supplement to a new drug submission for Nuvaxovid which works towards immunization to help prevent the coronavirus in individuals.

The approval was based on data from pediatric expansion of the phase 3 trial in the U.S. which has showed that effectiveness was higher in adolescents than in young adults.

Trials have found that protective efficacy was of 79.5% overall at a time when the Delta variant was the predominant circulating strain.

 

Write to Adriano Marchese at adriano.marchese@wsj.com

 

(END) Dow Jones Newswires

December 07, 2022 10:18 ET (15:18 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Novavax Charts.
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Novavax Charts.